Abstract:2022-RA-886-ESGO Figure 1 Conclusion 8.1% of endometrial cancer patients undergoing minimally invasive surgery with intrauterine manipulation showed positive peritoneal cytology conversion associated with significantly worse oncological outcome. 2022-RA-888-ESGO ROLE OF PREOPERATIVE DETERMINATION OF MOLECULAR CLASSIFICATION ON ENDOMETRIAL BIOPSY IN PREOPERATIVE ALLOCATION INTO A RISK CATEGORY IN ENDOMETRIAL CANCER Laura Cárdenas Puiggrós, Pedro Alberto Corzo Orantos, Anna Taltavull Pons, Isabel Núñez Márquez, Rocio Garcia BerrioCristina Meléndez Muñoz, Pilar Barretina Ginesta, Hugo Javier Rosales González, Eduard Sala Hernández, Elena Álvarez Castaño. Gynaecological Oncology Unit, Dr. Josep Trueta University Hospital, Girona, Spain; Pathology Department, Dr. Josep Trueta University Hospital, Girona, Spain; Medical Oncology, Catalan Institute of Oncology, Girona, Spain; Radiation Oncology, Catalan Institute of Oncology, Girona, Spain 10.1136/ijgc-2022-ESGO.254 Introduction/Background Traditional risk classification in endometrial cancer was based on clinicopathological data. Preoperative assessment is used to tailor the extend of surgery. The TCGA surrogate has been recently incorporated into risk stratification by ESGO-ESTRO-ESP guidelines. The aim of this study is to evaluate if preoperative determination of molecular classification is feasible and can improve preoperative estimation of risk group. Methodology In this retrospective cohort study, we identified all newly clinical early-stage endometrial cancer cases operated between January 2021 and April 2022. All cases had preoperative MRI and endometrial biopsy where molecular classification was done. Patients were allocated to a risk group based on 2021 ESGO-ESTRO-ESP guidelines by three Methods using only preoperative clinicopathological data, using preoperative molecular and clinicopathological data, using postoperative molecular and clinicopathological data. Results 55 cases were included. In all cases molecular classification was done preoperative while the patient was in waiting list. In figure 1, concordance between preoperative and postoperative assessment is shown. Abstract 2022-RA-888-ESGO Figure 1 Relation between preoperative and postoperative risk assessment2022-RA-888-ESGO Figure 1 Relation between preoperative and postoperative risk assessment When molecular classification is only taken account postoperatively, the Cohen’s kappa coefficient for the concordance is 0.37 (95% CI= 0.20–0.54) and risk was underestimated in 16/55 (29.1%) and overestimated in 8/55 (14.5%). If molecular classification is added to preoperative assessment, the Cohen’s kappa coefficient is 0.54 (95% CI= 0.38–0.70) and risk was underestimated in 12/55 (21.9%) and overestimated in 5/55 (10.0%). Overall agreement between preoperative and postoperative assessment for hystotype was 89.1%, for grade was 74.5%, and between radiologic and definitive stage was 74.5%. Conclusion Preoperative determination of molecular classification is feasible and seems to increase the reliability of preoperative risk stratification. However, in around 22% of cases risk is still underestimated leading to inadequate surgery strategy. Sentinel lymph node biopsy can elegantly overcome this problem by providing information on the lymph node status with minimal morbidity and its implementation should be

Treatment efficacy implications of incorrect utilization of tumor marker levels and risk group assignment according to the International Germ Cell Consensus Classification (IGCCCG).

Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma

Primary retroperitoneal germ-cell tumours (pR-GCT): Evaluation of treatment outcomes of an international retrospective collaboration (PRIMERE study).

Inconsistency in the assessment of retroperitoneal lymph node metastasis in patients with testicular cancer: Influence on clinical stage, therapy and relapse rate.

Roles of Tumor Markers in Central Nervous System Germ Cell Tumors Revisited with Histopathology-Proven Cases in a Large International Cohort

Predicting outcomes in malignant ovarian germ cell tumors using the modified International Germ Cell Cancer Collaborative Group classification system

Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium

Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis

The Values of Systemic Immune-Inflammation Index and Neutrophil-Lymphocyte Ratio in Predicting Testicular Germ Cell Tumors: A Retrospective Clinical Study.

Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses

Outcomes after primary retroperitoneal lymph node dissection in men with stage 2 non-seminomatous germ cell tumour: A multicenter retrospective cohort study.

Impact on Clinical Stage and Treatment

Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients with non-seminomatous germ-cell tumor (NSGCT).

Clinical outcome and prognostic factors for immunotherapy-based treatments in patients with platinum-refractory germ cell tumor

Pathologic findings and clinical outcomes in patients who required neoadjuvant chemotherapy before orchiectomy for testicular germ cell tumors

Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment

2022-RA-888-ESGO Role of preoperative determination of molecular classification on endometrial biopsy in preoperative allocation into a risk category in endometrial cancer

Half of oncologists fail to use ordered NGS results to guide their first-line treatment decision in advanced NSCLC: A retrospective study in a community-based integrated healthcare system

Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer

A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer

Identification of a panel of microRNA biomarkers for the management of patients with refractory germ cell tumor of the testis.